BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 09:40PM GMT
Release Date Price: €18.3 (+2.58%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Great. Welcome, everyone, and welcome, especially to the team from BioXcel Therapeutics. Today, we have Vimal Mehta, CEO; Rob Risinger, CMO; and then we've got Matt Wiley, Chief Commercial Officer. So thanks to all of you for joining, and thanks to everyone who's joining us here and on the webcast.

Questions & Answers

Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - VP

Maybe just to start, could you level set with a brief overview of the company with perhaps a particular focus on what you see as key value drivers over the next 12 to 24 months?

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Great. Thank you, Corinne, for hosting us, and good afternoon, everyone. BioXcel Therapeutics is a biopharmaceutical company developing innovative medicines in neuroscience and immuno-oncology using artificial intelligence-based platform.

In terms of where we are, we've been now, like a public

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot